Summit Therapeutics (SMMT) Retained Earnings (2018 - 2026)

Summit Therapeutics (SMMT) has reported Retained Earnings for 9 consecutive years, with $3.3 billion the latest figure, recorded in Q2 2026.

• Quarterly Retained Earnings rose 58.44% year-over-year to $3.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.3 billion (up 58.44% YoY) and the FY2025 annual result came in at $2.9 billion, up 84.44% from the prior year.
• Retained Earnings advanced to $3.3 billion in Q2 2026 per SMMT's latest filing, from $3.0 billion in the prior quarter.
• Over the last five years, Retained Earnings for SMMT reached as high as $3.3 billion in Q2 2026 and fell as low as $388.3 million in Q1 2022.
• A 5-year average of $1.5 billion and a median of $1.2 billion in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2023 — Retained Earnings surged 170.03% — and 2024, when it increased 2.65%.
• Year by year, Retained Earnings stood at $504.8 million in 2022, then surged by 111.26% to $1.1 billion in 2023, then jumped by 49.87% to $1.6 billion in 2024, then jumped by 84.44% to $2.9 billion in 2025, then gained by 12.76% to $3.3 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $3.3 billion, $3.0 billion, and $2.9 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.